Cedar Creek tracks DeepIntent’s borrowing with SLR Investment to estimate Propel Media’s growth. Dividend delay noted. Read ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Prucalopride Tablets, 1 mg and 2 mg (USRLD: Motegrity Tablets, 1 mg and 2 mg).

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets ...

Glucagon injection salesdeclined 25% to $20.6 million in Q2 2025, driven by increased competition and a market shift toward ...